LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

94.79 2.81

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

90.71

Максимум

94.96

Ключови измерители
By Trading Economics
Приходи	-6.3M -53M
Продажби	2.8M 51M
EPS	-0.82
Марж на печалбата	-103.131
Служители	283
EBITDA	-7.6M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+51.29% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.1B 6.4B
Предишно отваряне	91.98
Предишно затваряне	94.79

Настроения в новините

By Acuity

34%

66%

77 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2.03.2026 г., 23:26 ч. UTC

Значими събития в новините

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2.03.2026 г., 22:21 ч. UTC

Пазарно говорене

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2.03.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2.03.2026 г., 22:06 ч. UTC

Пазарно говорене

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Energy & Utilities Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

2.03.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2.03.2026 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2.03.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 21:17 ч. UTC

Значими събития в новините

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2.03.2026 г., 20:44 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:43 ч. UTC

Пазарно говорене

Значими събития в новините

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2.03.2026 г., 20:28 ч. UTC

Печалби

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2.03.2026 г., 20:25 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2.03.2026 г., 20:24 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 20:12 ч. UTC

Значими събития в новините

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2.03.2026 г., 20:05 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

51.29% нагоре

12-месечна прогноза

Среден 140.29 USD 51.29%

Висок 176 USD

Нисък 110 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

77 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.